Nystatin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Nystatin: From Antifungal Therapy (Established Use) to Predicted Vulvovaginitis Indication
One-Sentence Summary
Nystatin is a polyene antifungal that disrupts fungal cell membranes by binding ergosterol; detailed original-indication and regulatory history are not available in the current dataset, and the drug is currently not marketed in Taiwan. The TxGNN model predicts continued/expanded efficacy for Vulvovaginitis (Candida-driven vaginal inflammation), with a 99.92% prediction score, 0 registered clinical trials, and 20 supporting publications (mostly reviews, one cohort study). Notably, the underlying rationale indicates this is likely an already-established antifungal indication captured by the knowledge graph rather than a genuinely novel repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in dataset — no license or original-indication records found |
| Predicted New Indication | Vulvovaginitis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L3 |
| Taiwan Market Status | ✗ Not Marketed (未上市) |
| Number of Licenses (NDAs) | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured drug profile (original_moa: [Data Gap]). However, the prediction rationale supplied with this evidence pack describes Nystatin as a polyene antifungal that binds ergosterol in fungal cell membranes, disrupting membrane permeability and causing fungal cell death.
Vulvovaginitis is predominantly caused by Candida albicans (85–90% of cases per the cited literature). Nystatin’s core antifungal mechanism maps directly onto this pathophysiology — there is no need to invoke an indirect or repurposed pathway, since topical/local antifungal treatment of candidal vulvovaginitis is a direct application of the drug’s known mode of action.
Importantly, the evidence pack itself flags a key caveat: this appears to be an already-established/traditional indication rather than a novel discovery. The high TxGNN score likely reflects pre-existing, well-documented drug–disease associations already embedded in the knowledge graph, not a new hypothesis requiring independent validation. This should be factored into any decision-making — the “prediction” largely confirms known clinical practice.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16047929 | 2005 | Cohort | Ceska gynekologie | Evaluated combined vaginal nystatin + nifuratel therapy for mixed/miscellaneous vulvovaginitis |
| 20406393 | 2011 | Clinical/In vitro | Mycoses | Correlated fluconazole/nystatin in vitro susceptibility with clinical outcomes in 283 patients with complicated VVC |
| 39771534 | 2024 | Review | Pharmaceutics | Update on managing fluconazole-resistant VVC; nystatin discussed as an alternative antifungal option |
| 30359236 | 2018 | Mechanistic (animal) | BMC Microbiology | Nystatin enhanced mucosal immune response and protected vaginal epithelial ultrastructure in a rat VVC model |
| 25775428 | 2015 | Review | BMJ Clinical Evidence | Overview of vulvovaginal candidiasis as second most common cause of vaginitis |
| 21774671 | 2011 | Review | J Women’s Health | Reviews boric acid and alternative therapies for recurrent VVC amid rising azole resistance |
| 21718579 | 2010 | Review | BMJ Clinical Evidence | Epidemiology and management overview of vulvovaginal candidiasis |
| 12228137 | 2002 | Review | BMJ | Clinical review of vulvovaginal candidiasis diagnosis and treatment |
| 11363911 | 1996 | Review | J Int Assoc Physicians AIDS Care | General review of candidiasis management |
| 4919155 | 1970 | Review | Med Clin North Am | Early foundational review of nystatin pharmacology and clinical use |
US Market Information
Currently no market authorization data available — Nystatin has 0 registered licenses and is not marketed in Taiwan under the current dataset.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack; TFDA label/warning data acquisition is flagged as a Blocking data gap — see Next Steps.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link is strong and direct (Nystatin’s known antifungal action against Candida directly explains efficacy in vulvovaginitis), and is supported by 20 publications including one cohort study — but there are no registered clinical trials for this specific indication, and the evidence pack itself suggests this may simply reflect an already-established clinical use rather than a new discovery requiring validation.
To proceed, the following is needed:
- Obtain TFDA label warnings/contraindications (Blocking gap, DG001) before any S1 safety assessment
- Obtain confirmed mechanism of action from DrugBank (High-priority gap, DG002)
- Clarify Taiwan market/licensing status and available dosage forms/routes (currently 0 licenses, “not marketed”) to assess feasibility of pursuing this indication locally
- Confirm whether related lower-confidence candidates in the same disease cluster (e.g., vulvitis, rank 8, evidence level L3; postmenopausal atrophic vaginitis, rank 6, evidence level L5 — likely a false positive due to lexical overlap with “vaginitis”) should be deprioritized or excluded from further review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.